
Brand Name | Status | Last Update |
|---|---|---|
| eluryng | ANDA | 2025-01-15 |
| enilloring | ANDA | 2024-06-24 |
| etonogestrel and ethinyl estradiol | ANDA | 2022-09-30 |
| etonogestrel and ethinyl estradiol vaginal | ANDA | 2024-07-08 |
| etonogestrel and ethinyl estradiol vaginal ring | ANDA | 2024-06-24 |
| etonogestrel/ethinyl estradiol | NDA authorized generic | 2025-02-26 |
| haloette | ANDA | 2024-04-19 |
| nexplanon | New Drug Application | 2024-12-13 |
| nuvaring | New Drug Application | 2025-10-01 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | — | — | 7 | 8 | 10 | 25 | 28 | 77 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | 2 | 7 | 2 | 12 |
| Uterine hemorrhage | D014592 | — | — | 1 | 4 | — | 4 | 1 | 9 |
| Contraception behavior | D003268 | — | — | 1 | — | 1 | 2 | 5 | 9 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | — | 3 | 3 | 8 |
| Hiv | D006678 | — | O98.7 | — | 1 | — | 3 | 3 | 7 |
| Drug interactions | D004347 | — | — | — | — | — | 3 | 2 | 5 |
| Menstruation disturbances | D008599 | — | N91.5 | 1 | 1 | — | 2 | 2 | 5 |
| Emergencies | D004630 | — | — | — | — | — | 3 | 1 | 4 |
| Metrorrhagia | D008796 | — | N92.1 | — | — | — | 2 | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dysmenorrhea | D004412 | — | N94.6 | — | 2 | 2 | — | — | 4 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperplasia | D006965 | EFO_0000536 | — | — | 1 | — | — | 1 | 2 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | 2 | 3 |
| Pregnancy rate | D018873 | — | — | 1 | — | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hormonal contraception | D000080282 | — | — | — | — | — | — | 2 | 2 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 2 | 2 |
| Weight loss | D015431 | — | — | — | — | — | — | 2 | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
| Microbiota | D064307 | — | — | — | — | — | — | 1 | 1 |
| Headache | D006261 | — | R51 | — | — | — | — | 1 | 1 |
| Pelvic pain | D017699 | — | — | — | — | — | — | 1 | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 1 | 1 |
| Sexual behavior | D012725 | — | — | — | — | — | — | 1 | 1 |
| Sexually transmitted diseases | D012749 | — | A50-A64 | — | — | — | — | 1 | 1 |
| Drug common name | Etonogestrel |
| INN | etonogestrel |
| Description | Etonogestrel is a medication which is used as a means of birth control for women. It is available as an implant placed under the skin of the upper arm under the brand names Nexplanon and Implanon. It is a progestin that is also used in combination with ethinylestradiol, an estrogen, as a vaginal ring under the brand names NuvaRing and Circlet. Etonogestrel is effective as a means of birth control and lasts at least three or four years with some data showing effectiveness for five years. Following removal, fertility quickly returns.
|
| Classification | Small molecule |
| Drug class | estrogens; progestins |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC |
| PDB | — |
| CAS-ID | 54048-10-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1531 |
| ChEBI ID | 50777 |
| PubChem CID | 21729469 |
| DrugBank | DB00294 |
| UNII ID | 304GTH6RNH (ChemIDplus, GSRS) |



















